research A Survey on Health Effects in a Human Population Exposed to Permanent‐Waving Solution Containing Thioglycolic Acid
Thioglycolic acid in hair products may pose reproductive and cancer risks for hairdressers.
Search
for
Sort by
Research
990-1000 / 1000+ results
research A NEW VITAMIN DEFICIENCY DETECTION SYSTEM
The system helps identify vitamin deficiencies early by analyzing symptoms.
research Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders
The immune processes causing VKH and vitiligo are similar in dogs and humans.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research A Timosaponin B‐II containing scalp care solution for improvement of scalp hydration, dandruff reduction, and hair loss prevention: A comparative study on healthy volunteers before and after application
The scalp care solution with Timosaponin B-II improved scalp hydration, reduced dandruff, and helped prevent hair loss.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
research Clinical response to oral tofacitinib in pediatric patients with alopecia areata
Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Cancer vaccine strategies and studies of human thioredoxin reductase splice variants
Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
Using finasteride with TIP extends time off period for prostate cancer patients.